Under settings, Modern will join IBM Quantum Accelerator programs and IBM Quantum Network and access to IBM’s quantum computing systems, together with IBM’s expertise in using those technologies. In addition, Moderna and IBM scientists will work together to use IBM’s MoLFormer, a trained AI model that infers molecular structures from simple representations to predict the physical properties of molecules. Moderna’s main goal is to optimize lipid nanoparticles, which encapsulate and protect mRNA as it moves through the body and to design mRNA drugs with optimal safety and performance. Additional information about this collaboration is available in a news release provided by IBM Here.
April 21, 2023